Targeted Radiopharmaceutical Therapy: Advances, Investment Dynamics, and Future Directions—Part 2

Radiopharmaceutical therapy is rapidly expanding, propelled by scientific and investment momentum. This paper analyzes the evolving dynamics of clinical innovation, infrastructure build-out, and financial investment that are shaping the competitive landscape. Platform validation, theranostic integration, and novel α-emitting isotopes are redefining early-stage development and investor interest. Although lead assets remain the primary driver of mergers and acquisitions, scalable manufacturing and supply security increasingly influence deal rationale. Distinct business models are emerging between vertically integrated players and network-based collaborators, each with distinct capital and operational trade-offs. Clinical adoption hinges on improved access to imaging, adaptive trial designs, and evolving reimbursement frameworks. Developers and investors must navigate a complex but rapidly maturing radiopharmaceutical therapy field, focusing on differentiation and manufacturing readiness to align with regulatory and payer expectations.